Treace Medical Concepts (TMCI) to Release Quarterly Earnings on Friday

Treace Medical Concepts (NASDAQ:TMCI) is projected to release its Q2 2026 results before the market opens on Friday, August 7th. Analysts expect Treace Medical Concepts to announce earnings of ($0.30) per share and revenue of $44.02 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 7, 2026 at 8:00 AM ET.

Treace Medical Concepts (NASDAQ:TMCI) last released its earnings results on Friday, May 8th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.03. Treace Medical Concepts had a negative return on equity of 67.04% and a negative net margin of 29.44%.The firm had revenue of $47.20 million for the quarter, compared to analysts’ expectations of $45.96 million. On average, analysts expect Treace Medical Concepts to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Treace Medical Concepts Trading Up 1.3%

Shares of NASDAQ TMCI opened at $4.74 on Wednesday. Treace Medical Concepts has a fifty-two week low of $1.17 and a fifty-two week high of $7.78. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.53 and a current ratio of 3.58. The company has a market cap of $307.48 million, a price-to-earnings ratio of -4.89 and a beta of 1.37. The business’s 50 day moving average price is $4.09 and its 200-day moving average price is $2.70.

Insider Buying and Selling at Treace Medical Concepts

In other news, CEO John T. Treace purchased 22,887 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was purchased at an average price of $4.04 per share, for a total transaction of $92,463.48. Following the completion of the acquisition, the chief executive officer owned 7,376,150 shares of the company’s stock, valued at approximately $29,799,646. This trade represents a 0.31% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders have purchased a total of 371,600 shares of company stock worth $1,104,801 over the last ninety days. Insiders own 23.42% of the company’s stock.

Institutional Investors Weigh In On Treace Medical Concepts

A number of institutional investors and hedge funds have recently bought and sold shares of TMCI. Bank of America Corp DE grew its position in shares of Treace Medical Concepts by 18.4% during the 3rd quarter. Bank of America Corp DE now owns 85,905 shares of the company’s stock worth $576,000 after buying an additional 13,332 shares in the last quarter. Jump Financial LLC bought a new stake in shares of Treace Medical Concepts in the fourth quarter valued at about $380,000. Creative Planning raised its holdings in shares of Treace Medical Concepts by 40.5% in the third quarter. Creative Planning now owns 46,110 shares of the company’s stock valued at $309,000 after acquiring an additional 13,301 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in Treace Medical Concepts by 133,241.9% in the second quarter. Russell Investments Group Ltd. now owns 41,336 shares of the company’s stock worth $243,000 after acquiring an additional 41,305 shares during the period. Finally, Barclays PLC lifted its stake in Treace Medical Concepts by 7.4% in the fourth quarter. Barclays PLC now owns 87,664 shares of the company’s stock worth $215,000 after acquiring an additional 6,077 shares during the period. 84.08% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Weiss Ratings raised Treace Medical Concepts from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 15th. Truist Financial lifted their target price on Treace Medical Concepts from $2.00 to $4.00 and gave the stock a “hold” rating in a research report on Thursday, July 16th. Finally, Wall Street Zen raised shares of Treace Medical Concepts from a “sell” rating to a “hold” rating in a research note on Saturday, June 20th. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Reduce” and an average price target of $4.97.

About Treace Medical Concepts

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.